Bora Pharmaceuticals acquires Eden Biologics CDMO Assets
share
Excerpt
Bora announced that as part of its five-year growth plan, it will initially invest $50 million USD and up to $100 million USD in the acquisition of Eden Biologics’ CDMO assets in Taiwan.
Article Summary
Bora Pharmaceuticals, Taiwan’s leading international contract development and manufacturing company (CDMO), has just announced the establishment of Bora Biologics Co., Ltd., a biologics-focused CDMO platform. In addition to Bora, Taishin Healthcare Limited Partnership and Tanvex BioPharma founder Allen Chao are also investors in the new entity.
The company also announced that as part of its 5-year growth plan, Bora will invest $50 million USD and up to $100 million USD in the acquisition of Eden Biologics’ CDMO assets in Taiwan. With its comprehensive CDMO customer services and competitive market share, Bora has established a leadership position in Taiwan as a CDMO for small molecules and biological macromolecules.
The strategic acquisition of Eden Biologics CDMO assets, located in Hsinchu Biomedical Science Park, Taiwan, will help Bora Group rapidly build a presence in the biological macromolecules and cell and gene therapy markets, and position the organization to expand its service offering to their clients supporting new and innovative drug development.
Bora will have biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, upstream and downstream processes, establishment of quality control and inspection specifications, as well as cell bank generation with the acquisition of the facility.
Bora Vice President Simon Chen commented, “The addition of the CDMO facilities state of the art equipment and the expertise of the highly qualified team gives Bora Biologics the ability to develop and continue with our clients as they progress to commercialization.”
About Bora Pharmaceuticals
Bora Pharmaceuticals is a premier international CDMO specializing in a wide range of complex dosage forms including oral solid, liquid, and semi-solid capabilities for both Rx and OTC products, as well as macromolecule biologics. Bora owns and operates multiple cGMP manufacturing facilities in Asia and North America offering services for clinical and commercial manufacturing, packaging, and analytical testing.
